Protalix BioTherapeutics, Inc.
PLX
$1.66
$0.085.06%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.79% | 0.18% | -18.47% | -28.22% | -43.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.79% | 0.18% | -18.47% | -28.22% | -43.59% |
| Cost of Revenue | 1.95% | 32.88% | 5.82% | 77.26% | 37.98% |
| Gross Profit | 191.01% | -19.62% | -31.60% | -65.23% | -74.88% |
| SG&A Expenses | -24.92% | -21.91% | -18.49% | -4.15% | 10.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.67% | 6.87% | -10.09% | 9.05% | -4.14% |
| Operating Income | 155.64% | -42.60% | -62.55% | -165.59% | -219.79% |
| Income Before Tax | 153.39% | -23.84% | -51.51% | -181.38% | -252.51% |
| Income Tax Expenses | 497.59% | 1,678.48% | 381.10% | -98.46% | -144.14% |
| Earnings from Continuing Operations | 142.70% | -42.93% | -64.73% | -190.49% | -265.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 142.70% | -42.93% | -64.73% | -190.49% | -265.08% |
| EBIT | 155.64% | -42.60% | -62.55% | -165.59% | -219.79% |
| EBITDA | 170.94% | -35.93% | -55.19% | -151.75% | -200.47% |
| EPS Basic | 145.29% | -49.10% | -65.12% | -198.07% | -328.54% |
| Normalized Basic EPS | 155.88% | -33.43% | -53.04% | -185.23% | -295.05% |
| EPS Diluted | 123.75% | -3.38% | -85.22% | -463.52% | -2,230.10% |
| Normalized Diluted EPS | 137.58% | -39.49% | -71.64% | -234.38% | -506.35% |
| Average Basic Shares Outstanding | 2.68% | 3.02% | 7.63% | 17.92% | 29.28% |
| Average Diluted Shares Outstanding | 13.44% | 7.30% | 11.72% | 8.92% | 25.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |